Axura

RSS

memantine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Axura. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Axura.

This EPAR was last updated on 12/05/2021

Authorisation details

Product details
Name
Axura
Agency product number
EMEA/H/C/000378
Active substance
memantine hydrochloride
International non-proprietary name (INN) or common name
memantine
Therapeutic area (MeSH)
Alzheimer Disease
Anatomical therapeutic chemical (ATC) code
N06DX01
Publication details
Marketing-authorisation holder
Merz Pharmaceuticals GmbH
Revision
26
Date of issue of marketing authorisation valid throughout the European Union
17/05/2002
Contact address
Eckenheimer Landstr. 100
D-60318 Frankfurt
Germany

Product information

18/03/2021 Axura - EMEA/H/C/000378 - WS/1980

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other anti-dementia drugs

Therapeutic indication

Treatment of patients with moderate to severe Alzheimer's disease.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings